232 related articles for article (PubMed ID: 14647149)
41. Paclitaxel in salvage therapy for germ cell tumors.
Motzer RJ
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-83-S15-85. PubMed ID: 9346229
[TBL] [Abstract][Full Text] [Related]
42. Modulation of cytostatic drugs by nifedipine in two heterotransplanted human testicular-cancer cell lines differing in their sensitivity to standard agents.
Bokemeyer C; Dunn T; Harstrick A; Lerch T; Poliwoda H; Schmoll HJ
Int J Cancer; 1994 Feb; 56(3):452-6. PubMed ID: 7906255
[TBL] [Abstract][Full Text] [Related]
43. Curing metastatic cancer: lessons from testicular germ-cell tumours.
Masters JR; Köberle B
Nat Rev Cancer; 2003 Jul; 3(7):517-25. PubMed ID: 12835671
[TBL] [Abstract][Full Text] [Related]
44. cis-Diammine-1, 1-cyclobutane dicarboxylate platinum II (carboplatin) in the treatment of testicular germ-cell tumours: a preliminary report.
Peckham MJ; Horwich A; Brada M; Drury A; Hendry WF
Cancer Treat Rev; 1985 Sep; 12 Suppl A():101-10. PubMed ID: 3002622
[TBL] [Abstract][Full Text] [Related]
45. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP
J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194
[TBL] [Abstract][Full Text] [Related]
46. Chemotherapy for good-risk germ-cell tumors.
Ryan CJ; Bajorin DF
Semin Urol Oncol; 2002 Nov; 20(4):244-50. PubMed ID: 12489057
[TBL] [Abstract][Full Text] [Related]
47. Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review.
Shelley MD; Burgon K; Mason MD
Cancer Treat Rev; 2002 Oct; 28(5):237-53. PubMed ID: 12435371
[TBL] [Abstract][Full Text] [Related]
48. Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts.
Dunn TA; Grünwald V; Bokemeyer C; Casper J
Invest New Drugs; 1997; 15(2):91-8. PubMed ID: 9220287
[TBL] [Abstract][Full Text] [Related]
49. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
Lotz JP; André T; Donsimoni R; Firmin C; Bouleuc C; Bonnak H; Merad Z; Esteso A; Gerota J; Izrael V
Cancer; 1995 Feb; 75(3):874-85. PubMed ID: 7828139
[TBL] [Abstract][Full Text] [Related]
50. Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples.
Lobo J; Constâncio V; Leite-Silva P; Guimarães R; Cantante M; Braga I; Maurício J; Looijenga LHJ; Henrique R; Jerónimo C
Clin Epigenetics; 2021 Apr; 13(1):70. PubMed ID: 33823933
[TBL] [Abstract][Full Text] [Related]
51. Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles.
Duale N; Lindeman B; Komada M; Olsen AK; Andreassen A; Soderlund EJ; Brunborg G
Mol Cancer; 2007 Aug; 6():53. PubMed ID: 17711579
[TBL] [Abstract][Full Text] [Related]
52. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
[TBL] [Abstract][Full Text] [Related]
53. Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors.
Mayer F; Honecker F; Looijenga LH; Bokemeyer C
Ann Oncol; 2003 Jun; 14(6):825-32. PubMed ID: 12796018
[TBL] [Abstract][Full Text] [Related]
54. Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells.
Gerwing M; Jacobsen C; Dyshlovoy S; Hauschild J; Rohlfing T; Oing C; Venz S; Oldenburg J; Oechsle K; Bokemeyer C; von Amsberg G; Honecker F
J Cancer Res Clin Oncol; 2016 Sep; 142(9):1979-94. PubMed ID: 27424191
[TBL] [Abstract][Full Text] [Related]
55. Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation.
Robertson KA; Bullock HA; Xu Y; Tritt R; Zimmerman E; Ulbright TM; Foster RS; Einhorn LH; Kelley MR
Cancer Res; 2001 Mar; 61(5):2220-5. PubMed ID: 11280790
[TBL] [Abstract][Full Text] [Related]
56. Survival of patients with viable malignant non-seminomatous germ cell tumour persistent after cisplatin-based induction chemotherapy.
Hollender A; Stenwig EA; Ous S; Fosså SD
Eur Urol; 1997; 31(2):141-7. PubMed ID: 9076455
[TBL] [Abstract][Full Text] [Related]
57. Treatment in germ cell tumours: state of the art.
Tjan-Heijnen VC; Oosterhof GO; de Wit R; De Mulder PH
Eur J Surg Oncol; 1997 Apr; 23(2):110-7. PubMed ID: 9158183
[TBL] [Abstract][Full Text] [Related]
58. The role of reactive oxygen species in cisplatin-induced apoptosis in human malignant testicular germ cell lines.
Schweyer S; Soruri A; Heintze A; Radzun HJ; Fayyazi A
Int J Oncol; 2004 Dec; 25(6):1671-6. PubMed ID: 15547704
[TBL] [Abstract][Full Text] [Related]
59. Future trials in germ cell malignancy (GCM) of the testis.
Oliver RT
Eur J Surg Oncol; 1997 Apr; 23(2):117-22. PubMed ID: 9158184
[TBL] [Abstract][Full Text] [Related]
60. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]